Adipokines, inflammation, and the endothelium in diabetes

Current Diabetes Reports

Volumn 3, Issue 4, 2003, Pages 293-298

  Aldhahi, Waleed ^a   Hamdy, Osama ^a  

^a JOSLIN DIABETES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; C REACTIVE PROTEIN; CYTOKINE; ENDOTHELIN 1; GLUCOSE TRANSPORTER 4; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLIXIMAB; INSULIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; LEPTIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PLASMINOGEN ACTIVATOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; RESISTIN; TROGLITAZONE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; UROKINASE; VASCULAR CELL ADHESION MOLECULE 1; SIGNAL PEPTIDE;

ADIPOSE TISSUE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CORONARY ARTERY DISEASE; CYTOKINE PRODUCTION; DIABETES MELLITUS; ENDOCRINE FUNCTION; HUMAN; IMMUNE SYSTEM; INFLAMMATION; INSULIN RESISTANCE; INSULIN SENSITIVITY; METABOLIC REGULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PROTEIN EXPRESSION; REVIEW; SUBCUTANEOUS TISSUE; VASCULAR DISEASE; VASCULAR ENDOTHELIUM; VISCERA; WEIGHT REDUCTION; BIOSYNTHESIS; EXERCISE; IMMUNOLOGY; PHYSIOLOGY; PROTEIN SYNTHESIS;

ADIPONECTIN; ADIPOSE TISSUE; CYTOKINES; DIABETES MELLITUS, TYPE 2; ENDOTHELIUM, VASCULAR; EXERCISE; HUMANS; INSULIN RESISTANCE; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; INTERLEUKIN-6; OBESITY; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN BIOSYNTHESIS; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR DISEASES; WEIGHT LOSS;

EID: 0141448772     PISSN: 15344827     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11892-003-0020-2     Document Type: Review

References (63)

1. Flegal KM, Carroll MD, Ogden CL, Johnson CL: Prevalence and trends in obesity among US adults, 1999-2000. JAMA 2000, 288:1723-1727.
2. Balkau B, Eschwege E, Papoz L, et al.: Risk factors for early death in non-insulin dependent diabetes and men with known glucose intolerance status. BMJ 1993, 307:295-299.
3. Bergman RN, Mittelman SD: Central role of the adipocyte in insulin resistance. J Basic Clin Physiol Pharmacol 1998, 9:205-221.
4. Saltiel AR: You are what you secrete. Nat Med 2001, 7:887-888
5. Coppack SW: Pro-inflammatory cytokines and adipose tissue. Proc Nutr Soc 2001, 60:349-356.
6. Mohamed-Ali V, Goodrick S, Bulmer K, et al.: Production of soluble tumor necrosis factor receptors by human subcutaneous adipose tissue in vivo. Am J Physiol 1999, 277(6 Pt 1):E971-E975.
7. Hotamisligil GS, Arner P, Caro JF, et al.: Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest 1995, 95:2409-2415.
8. Arner P: Regional differences in protein production by human adipose tissue. Biochem Soc Trans 2001, 29(Pt 2):72-75.
9. Mohamed-Ali V, Goodrick S, Rawesh A, et al.: Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab 1997, 82:4196-4200.
10. Scherer PE, Williams S, Fogliano M, et al.: A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 1995, 270:26746-26749.
11. Maeda K, Okubo K, Shimomura I, et al.: cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). Biochem Biophys Res Commun 1996, 221:286-289.
12. Steppan CM, Bailey ST, Bhat S, et al.: The hormone resistin links obesity to diabetes. Nature 2001, 409:307-312.
13. Friedman J: Fat in all the wrong places. Nature 2002, 415:268-269.
14. Dua A, Hennes MI, Hoffmann RG, et al.: Leptin: a significant indicator of total body fat but not of visceral fat and insulin insensitivity in African-American women. Diabetes 1996, 45:1635-1637.
15. Shimomura I, Funahashi T, Takahashi M, et al.: Enhanced expression of PAI-1 in visceral fat: possible contributor to vascular disease in obesity. Nat Med 1996, 2:800-803.
16. Ross R: Atherosclerosis - an inflammatory disease. N Engl J Med 1999, 340:115-126.
17. Yuan M, Konstantopoulos N, Lee J, et al.: Reversal of obesity-and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta. Science 2001, 293:1673-1677.
18. Ventre J, Doebber T, Wu M, et al.: Targeted disruption of the tumor necrosis factor-alpha gene: metabolic consequences in obese and nonobese mice. Diabetes 1997, 46:1526-1531.
19. Katsuki A, Sumida Y, Murashima S, et al.: Serum levels of tumor necrosis factor-alpha are increased in obese patients with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1998, 83:859-862.
20. Katsuki A, Sumida Y, Murata K, et al.: Troglitazone reduces plasma levels of tumor necrosis factor-alpha in obese patients with type 2 diabetes. Diabetes Obes Metab 2000, 2:189-191.
21. Stephens JM, Pekala PH: Transcriptional repression of the GLUT4 and C/EBP genes in 3T3-L1 adipocytes by tumor necrosis factor-alpha. J Biol Chem 1991, 266:21839-21845.
22. Hotamisligil GS, Peraldi P, Budavari A, et al.: IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science 1996, 271:665-668.
23. Strassmann G, Fong M, Windsor S, Neta R: The role of interleukin-6 in lipopolysaccharide-induced weight loss, hypoglycemia and fibrinogen production, in vivo. Cytokine 1993, 5:285-290.
24. Pradhan AD, Manson JE, Rifai N, et al.: C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001, 286:327-334.
25. Bastard JP, Jardel C, Bruckert E, et al.: Elevated levels of interleukin 6 are reduced in serum and subcutaneous adipose tissue of obese women after weight loss. J Clin Endocrinol Metab 2000, 85:3338-342.
26. Maeda N, Shimomura I, Kishida K, et al.: Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med 2002, 8:731-737.
27. Yamauchi T, Kamon J, Waki H, et al.: The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001, 7:941-946.
28. Calles-Escandon J, Mirza SA, Sobel BE, Schneider DJ: Induction of hyperinsulinemia combined with hyperglycemia and hypertriglyceridemia increases plasminogen activator inhibitor 1 in blood in normal human subjects. Diabetes 1998, 47:290-293.
29. McGill JB, Schneider DJ, Arfken CL, et al.: Factors responsible for impaired fibrinolysis in obese subject and NIDDM patients. Diabetes 1994, 43:104-109.
30. Havel PJ, Kasim-Karakas S, Mueller W, et al.: Relationship of plasma leptin to plasma insulin and adiposity in normal weight and overweight women: effects of dietary fat content and sustained weight loss. J Clin Endocrinol Metab 1996, 81:406-413.
31. Hube F, Hauner H: The role of TNF-alpha in human adipose tissue: prevention of weight gain at the expense of insulin resistance? Horm Metab Res 1999, 31:626-631.
32. Ehtisham NZ: Do resistin resist insulin? Curr Sci 2002, 83:1190-1191.
33. Nagaev I, Smith U: Insulin resistance and type 2 diabetes are not related to resistin expression in human fat cells or skeletal muscle. Biochem Biophys Res Commun 2001, 285:561-564.
34. Tooke JE, Hannemann MM: Adverse endothelial function and the insulin resistance syndrome. J Intern Med 2000, 247:425-431.
35. Bucala R, Tracey KJ, Cerami A: Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. J Clin Invest 1991, 87:432-438.
36. Gearing AJH, Hemingway J, Pigott R, et al.: Soluble forms of vascular adhesion molecules, E-selectin, ICAM-1, and VCAM-1. Pathological significance. Ann N Y Acad Sci 1992, 667:324-331.
37. Campbell JH, Campbell GR: Cell biology of atherosclerosis. J Hypertension 1994, 12:S129-S132.
38. Morise T, Takeuchi Y, Kawano M, et al.: Increased plasma levels of immunoreactive endothelin and von Willebrand factor in NIDDM patients. Diabetes Care 1995, 18:87-89.
39. Jovinge S, Hamsten A, Tornvall P, Proudler A: Evidence for a role of tumor necrosis factor alpha in disturbances of triglyceride and glucose metabolism predisposing to coronary heart disease. Metabolism 1998, 47:113-18.
40. Zeng M, Zhang H, Lowell C, He P: Tumor necrosis factor-alpha-induced leukocyte adhesion and microvessel permeability. Am J Physiol Heart Circ Physiol 2002, 283:H2420-H2430.
41. Ridker PM, Rifai N, Pfeffer M, et al.: Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction. Circulation 2000, 101:2149-2153.
42. Ziccardi P, Nappo F, Giugliano G, et al.: Reduction of inflammatory cytokine concentrations and improvement of endothelial functions in obese women after weight loss over one year. Circulation 2002, 105:804-809.
43. Hurlimann D, Forster A, Noll G, et al.: Anti-tumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis. Circulation 2002, 106:2184-2187.
44. Kirchgessner TG, Uysal KT, Wiesbrock SM, et al.: Tumor necrosis factor-alpha contributes to obesity-related hyperleptinemia by regulating leptin release from adipocytes. J Clin Invest 1997, 100:2777-2782.
45. Ashton AW, Ware GM, Kaul DK, Ware JA: Inhibition of tumor necrosis factor alpha-mediated NFkappa B activation and leukocyte adhesion, with enhanced endothelial apoptosis, by G protein-linked receptor (TP) ligands. J Biol Chem 2003, 278:11858-11866.
46. Patel JN, Jager A, Schalkwijk C, et al.: Effects of tumor necrosis factor-alpha in the human forearm: blood flow and endothelin-1 release. Clin Sci 2002, 103:409-415.
47. Weber C, Negrescu E, Erl W, Pietsch A: Inhibitors of protein tyrosine kinase suppress TNF-stimulated induction of endothelial cell adhesion molecules. Immunology 1995, 155:445-451.
48. Uzui H, Harpf A, Liu M, et al.: Increased expression of membrane type 3-matrix metalloproteinase in human atherosclerotic plaque: role of activated macrophages and inflammatory cytokines. Circulation 2002, 106:3024-3030.
49. Ridker PM, Rifai N, Stampfer MJ, Hennekens CH: Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000, 101:1767-1772.
50. Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW: C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 1999, 19:972-978.
51. Romano M, Sironi M, Toniatti C, et al.: Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte. Immunity 1997, 6:315-325.
52. Heinrich PC, Castell JV, Andus T: Interleukin-6 and the acute phase response. Biochem J 1990, 265:621-636.
53. Blake GJ, Ridker PM: Inflammatory bio-markers and cardiovascular risk prediction. J Intern Med 2002, 252:283-294.
54. Matsuda M, Shimomura I, Sata M, et al.: Role of adiponectin in preventing vascular stenosis. The missing link of adipo-vascular axis. J Biol Chem 2002, 277:37487-37491.
55. Ouchi N, Kihara S, Arita Y, et al.: Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 1999, 100:2473-2476.
56. Okamoto Y, Kihara S, Ouchi N, et al.: Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation 2002, 106:2767-2770.
57. Calles-Escandon J, Cipolla M: Diabetes and endothelial dysfunction: a clinical perspective. Endocr Rev 2001, 22:36-52.
58. Minamikawa J, Yamauchi M, Inoue D, Koshiyama H: Another potential use of troglitazone in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1998, 83:1041-1042.
59. Bilsborough W, O'Driscoll G, Stanton K, et al.: Effect of lowering tumour necrosis factor-alpha on vascular endothelial function in type II diabetes. Clin Sci 2002, 103:163-169.
60. Ouchi N, Kihara S, Arita Y, et al.: Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation 2001, 103:1057-1063.
61. Hamdy O, Moussa A, Ledbury S, et al.: Effects of weight loss and increased physical activity on insulin and glucose dynamics in obese subjects with insulin resistance syndrome. Diabetes 2002, 51(suppl 2):A60.
62. Gabriely I, Ma XH, Yang XM, et al.: Removal of visceral fat prevents insulin resistance and glucose intolerance of aging: an adipokine-mediated process? Diabetes 2002, 51:2951-2958.
63. Brazilia N, She L, Liu BQ, et al.: Surgical removal of visceral fat reverses hepatic insulin resistance. Diabetes 1999, 48:94-98.